-+ 0.00%
-+ 0.00%
-+ 0.00%

Humacyte seeks FDA approval for engineered blood vessel in dialysis access

PUBT·11/19/2026 13:05:27
Listen to the news
Humacyte seeks FDA approval for engineered blood vessel in dialysis access
  • Humacyte submitted an FDA application to expand its acellular tissue engineered vessel into hemodialysis access, requesting priority review.
  • The proposed indication covers patients with end-stage kidney disease at increased risk of arteriovenous fistula maturation failure.
  • Three Phase 3 trials support the filing; V012 showed women achieved functional access sooner and spent less time using catheters versus fistulas.
  • V012 interim results were already presented at vascular surgery and nephrology meetings in June and October 2026, respectively.
  • Hemodialysis access would become the vessel’s second indication, following FDA clearance as Symvess for extremity vascular trauma in December 2024.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190800PRIMZONEFULLFEED9881043) on November 19, 2026, and is solely responsible for the information contained therein.